Sebia Developing Thalassemia Diagnostic with Inserm and Inserm Transfert
|
By LabMedica International staff writers Posted on 02 Jul 2012 |
|
Sebia (Norcross, GA, USA) has entered into partnership with Inserm (the French National Institute of Health and Medical Research; Paris, France) and Inserm Transfert (Paris, France), its private subsidiary responsible for marketing the outcomes of its scientific research, to develop and commercialize a biological test for measuring free alpha globin chains in beta-thalassaemic patients. The test will indicate the severity index of the disease in patients.
Sebia will support the research carried out by Inserm, who will then develop the test. In return, Sebia will have the possibility of acquiring exclusive rights to industrially develop and commercialize the test internationally.
The test is based on the interaction of the free alpha globin chain with the alpha hemoglobin stabilizing protein (AHSP). In the case of beta-thalassemias, there is a synthesis deficit in the beta chain, which has the effect of reducing the amount of hemoglobin A (HbA) in red blood cells and leading to an imbalance between the numbers of alpha and beta chains.
Thus, there is a relative excess of alpha chains. These chains are very unstable, and despite the fact that the AHSP plays the role of chaperone (capable of controlling and stabilizing them), in people suffering from beta-thalassemias, they form precipitates that act like oxidants and damage the cell, resulting in apoptosis (cell death) and inefficient erythropoiesis (red cell production).
The size of the pool of free alpha chains enables determination of the severity of the disease in thalassemia patients, and in patients with a synthesis imbalance in their globin chains.
“We were looking for a company that was interested in developing this test, and the choice fell quite naturally to Sebia, since we have known the company for a long time and its interest in researching diagnostic tools for hemoglobinopathies,” explained Véronique Baudin-Creuza, from Inserm unit U779 at the University of Paris-Sud 11 (Paris, France) and the unit for protein polymerization pathologies, blood substitutes and rare red blood-cell diseases at Bicêtre Hospital (Paris, France).
Related Links:
Sebia
Inserm
Inserm Transfert
Sebia will support the research carried out by Inserm, who will then develop the test. In return, Sebia will have the possibility of acquiring exclusive rights to industrially develop and commercialize the test internationally.
The test is based on the interaction of the free alpha globin chain with the alpha hemoglobin stabilizing protein (AHSP). In the case of beta-thalassemias, there is a synthesis deficit in the beta chain, which has the effect of reducing the amount of hemoglobin A (HbA) in red blood cells and leading to an imbalance between the numbers of alpha and beta chains.
Thus, there is a relative excess of alpha chains. These chains are very unstable, and despite the fact that the AHSP plays the role of chaperone (capable of controlling and stabilizing them), in people suffering from beta-thalassemias, they form precipitates that act like oxidants and damage the cell, resulting in apoptosis (cell death) and inefficient erythropoiesis (red cell production).
The size of the pool of free alpha chains enables determination of the severity of the disease in thalassemia patients, and in patients with a synthesis imbalance in their globin chains.
“We were looking for a company that was interested in developing this test, and the choice fell quite naturally to Sebia, since we have known the company for a long time and its interest in researching diagnostic tools for hemoglobinopathies,” explained Véronique Baudin-Creuza, from Inserm unit U779 at the University of Paris-Sud 11 (Paris, France) and the unit for protein polymerization pathologies, blood substitutes and rare red blood-cell diseases at Bicêtre Hospital (Paris, France).
Related Links:
Sebia
Inserm
Inserm Transfert
Gold Member
Hybrid Pipette
SWITCH
Silver Member
PCR Plates
Diamond Shell PCR Plates
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Latest Molecular Diagnostics News
- Simple Urine Test to Revolutionize Bladder Cancer Diagnosis and Treatment
- Blood Test to Enable Earlier and Simpler Detection of Liver Fibrosis
- Genetic Marker to Help Children with T-Cell Leukemia Avoid Unnecessary Chemotherapy
- Four-Gene Blood Test Rules Out Bacterial Lung Infection
- New PCR Test Improves Diagnostic Accuracy of Bacterial Vaginosis and Candida Vaginitis
- New Serum Marker-Editing Strategy to Improve Diagnosis of Neurological Diseases
- World’s First Genetic Type 1 Diabetes Risk Test Enables Early Detection
- Blood Test to Help Low-Risk Gastric Cancer Patients Avoid Unnecessary Surgery
- First-Of-Its-Kind Automated System Speeds Myeloma Diagnosis
- Blood Protein Profiles Predict Mortality Risk for Earlier Medical Intervention
- First Of Its Kind Blood Test Detects Gastric Cancer in Asymptomatic Patients
- Portable Molecular Test Detects STIs at POC in 15 Minutes
- Benchtop Analyzer Runs Chemistries, Immunoassays and Hematology in Single Device
- POC Bordetella Test Delivers PCR-Accurate Results in 15 Minutes
- Pinprick Blood Test Could Detect Disease 10 Years Before Symptoms Appear
- Refined C-Reactive Protein Cutoffs Help Assess Sepsis Risk in Preterm Babies
Channels
Clinical Chemistry
view channel
Chemical Imaging Probe Could Track and Treat Prostate Cancer
Prostate cancer remains a leading cause of illness and death among men, with many patients eventually developing resistance to standard hormone-blocking therapies. These drugs often lose effectiveness... Read more
Mismatch Between Two Common Kidney Function Tests Indicates Serious Health Problems
Creatinine has long been the standard for measuring kidney filtration, while cystatin C — a protein produced by all human cells — has been recommended as a complementary marker because it is influenced... Read more
Hematology
view channel
Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk
Early detection of Alzheimer’s disease remains one of the biggest unmet needs in neurology, particularly because the biological changes underlying the disorder begin decades before memory symptoms appear.... Read more
Microvesicles Measurement Could Detect Vascular Injury in Sickle Cell Disease Patients
Assessing disease severity in sickle cell disease (SCD) remains challenging, especially when trying to predict hemolysis, vascular injury, and risk of complications such as vaso-occlusive crises.... Read more
ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners
Direct oral anticoagulants (DOACs) are one of the most common types of blood thinners. Patients take them to prevent a host of complications that could arise from blood clotting, including stroke, deep... Read more
Immunology
view channel
New Test Distinguishes Vaccine-Induced False Positives from Active HIV Infection
Since HIV was identified in 1983, more than 91 million people have contracted the virus, and over 44 million have died from related causes. Today, nearly 40 million individuals worldwide live with HIV-1,... Read more
Gene Signature Test Predicts Response to Key Breast Cancer Treatment
DK4/6 inhibitors paired with hormone therapy have become a cornerstone treatment for advanced HR+/HER2– breast cancer, slowing tumor growth by blocking key proteins that drive cell division.... Read more
Chip Captures Cancer Cells from Blood to Help Select Right Breast Cancer Treatment
Ductal carcinoma in situ (DCIS) accounts for about a quarter of all breast cancer cases and generally carries a good prognosis. This non-invasive form of the disease may or may not become life-threatening.... Read more
Microbiology
view channel
Rapid Diagnostic Test Matches Gold Standard for Sepsis Detection
Sepsis kills 11 million people worldwide every year and generates massive healthcare costs. In the USA and Europe alone, sepsis accounts for USD 100 billion in annual hospitalization expenses.... Read more
Rapid POC Tuberculosis Test Provides Results Within 15 Minutes
Tuberculosis remains one of the world’s deadliest infectious diseases, and reducing new cases depends on identifying individuals with latent infection before it progresses. Current diagnostic tools often... Read more
Rapid Assay Identifies Bloodstream Infection Pathogens Directly from Patient Samples
Bloodstream infections in sepsis progress quickly and demand rapid, precise diagnosis. Current blood-culture methods often take one to five days to identify the pathogen, leaving clinicians to treat blindly... Read more
Pathology
view channel
Tunable Cell-Sorting Device Holds Potential for Multiple Biomedical Applications
Isolating rare cancer cells from blood is essential for diagnosing metastasis and guiding treatment decisions, but remains technically challenging. Many existing techniques struggle to balance accuracy,... Read more
AI Tool Outperforms Doctors in Spotting Blood Cell Abnormalities
Diagnosing blood disorders depends on recognizing subtle abnormalities in cell size, shape, and structure, yet this process is slow, subjective, and requires years of expert training. Even specialists... Read more
Technology
view channel
Artificial Intelligence Model Could Accelerate Rare Disease Diagnosis
Identifying which genetic variants actually cause disease remains one of the biggest challenges in genomic medicine. Each person carries tens of thousands of DNA changes, yet only a few meaningfully alter... Read more
AI Saliva Sensor Enables Early Detection of Head and Neck Cancer
Early detection of head and neck cancer remains difficult because the disease produces few or no symptoms in its earliest stages, and lesions often lie deep within the head or neck, where biopsy or endoscopy... Read more
Industry
view channel
Abbott Acquires Cancer-Screening Company Exact Sciences
Abbott (Abbott Park, IL, USA) has entered into a definitive agreement to acquire Exact Sciences (Madison, WI, USA), enabling it to enter and lead in fast-growing cancer diagnostics segments.... Read more
